Vivus Inc (VVUS):企業の財務・戦略的SWOT分析

◆英語タイトル:Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1653
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Vivus Inc (VVUS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vivus Inc (Vivus) is a biopharmaceutical company that develops and commercializes next-generation therapeutics for addressing unmet medical needs of obesity, sleep apnea, diabetes, and sexual health. The company markets phentermine and topiramate extended-release capsules for the chronic weight management in adult patients; avanafil, an oral phosphodiesterase type 5, for erectile dysfunction; and pancrelipase microtablets for exocrine pancreatic insufficiency. It is investigating its pipeline products for the treatment of obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, and pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product and pipeline portfolio. The company also has direct operations through its subsidiaries in Canada and the Netherlands. Vivus is headquartered in Campbell, California, the US.

Vivus Inc Key Recent Developments

Apr 03,2020 VitalTech partners with VIVUS Pharmaceuticals to accelerate launch of telehealth and remote patient monitoring modules
Apr 01,2020 VIVUS announces $11.55 million registered direct offering priced at-the-market under Nasdaq Rules
Mar 31,2020 VIVUS accelerates the launch of telemedicine and remote monitoring modules to facilitate effective patient care during “social distancing”
Mar 03,2020 VIVUS reports fourth quarter and full year 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Vivus Inc – Key Facts
Vivus Inc – Key Employees
Vivus Inc – Key Employee Biographies
Vivus Inc – Major Products and Services
Vivus Inc – History
Vivus Inc – Company Statement
Vivus Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Vivus Inc – Business Description
Product Category: License and Milestone Revenue
Performance
Product Category: Pancreaze/ Pancreaze MT (Net Product and Royalty Revenue)
Performance
Product Category: Qsymia (Net Product and Supply Revenue)
Performance
Product Category: Stendra/Spedra (Supply and Royalty Revenue)
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
Vivus Inc – Corporate Strategy
Vivus Inc – SWOT Analysis
SWOT Analysis – Overview
Vivus Inc – Strengths
Vivus Inc – Weaknesses
Vivus Inc – Opportunities
Vivus Inc – Threats
Vivus Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vivus Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 03, 2020: VitalTech partners with VIVUS Pharmaceuticals to accelerate launch of telehealth and remote patient monitoring modules
Apr 01, 2020: VIVUS announces $11.55 million registered direct offering priced at-the-market under Nasdaq Rules
Mar 31, 2020: VIVUS accelerates the launch of telemedicine and remote monitoring modules to facilitate effective patient care during “social distancing”
Mar 03, 2020: VIVUS reports fourth quarter and full year 2019 financial results
Nov 05, 2019: VIVUS reports third quarter 2019 financial results
Oct 28, 2019: VIVUS announces departures of Eric W. Roberts and Allan L. Shaw from Board of Directors
Aug 06, 2019: VIVUS reports second quarter 2019 financial results
Apr 30, 2019: VIVUS Reports First Quarter 2019 Financial Results
Feb 26, 2019: VIVUS announces fourth quarter 2018 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Vivus Inc, Key Facts
Vivus Inc, Key Employees
Vivus Inc, Key Employee Biographies
Vivus Inc, Major Products and Services
Vivus Inc, History
Vivus Inc, Subsidiaries
Vivus Inc, Key Competitors
Vivus Inc, Ratios based on current share price
Vivus Inc, Annual Ratios
Vivus Inc, Annual Ratios (Cont...1)
Vivus Inc, Annual Ratios (Cont...2)
Vivus Inc, Interim Ratios
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vivus Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Vivus Inc, Performance Chart (2015 - 2019)
Vivus Inc, Ratio Charts
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Vivus Inc (VVUS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xinjiang Goldwind Science & Technology Co Ltd (002202):電力:M&Aディール及び事業提携情報
    Summary Xinjiang GoldWind Science & Technology Co. Ltd. (Goldwind) is a wind energy company that manufactures wind turbine generator sets, develops wind farms and provides wind power services. The company researches, develops, manufactures and sells wind turbine generators and wind power components. …
  • Eiger BioPharmaceuticals Inc (EIGR):製薬・医療:M&Aディール及び事業提携情報
    Summary Eiger BioPharmaceuticals Inc (Eiger), formerly Celladon Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercializationof novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which are …
  • Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS- …
  • Pfizer Inc (PFE):企業の財務・戦略的SWOT分析
    Pfizer Inc (PFE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Tecpetrol S.A.:企業の戦略・SWOT・財務情報
    Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report Summary Tecpetrol S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Noble Energy Inc (NBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventional and global offshore conventional assets. Noble has operations in the Denver-Julesburg (DJ) B …
  • Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the o …
  • Myer Holdings Ltd:企業の戦略・SWOT・財務分析
    Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Myer Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • FXI, Inc.:企業の戦略的SWOT分析
    FXI, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Indivumed GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Indivumed GmbH (Indivumed) is an oncology company that provides solutions for diagnosis and treatment of cancer. The company is involved in the generation, characterization, and analysis of biologic samples from human cancer patients. It offers biospecimen products and clinical data sets; an …
  • Triskalia SCA:企業の戦略・SWOT・財務情報
    Triskalia SCA - Strategy, SWOT and Corporate Finance Report Summary Triskalia SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Stantec Inc (STN)-エネルギー分野:企業M&A・提携分析
    Summary Stantec Inc. (Stantec) is a consulting services company offering architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engineering, landscape architectu …
  • PT. SOHO Industri Pharmasi:製薬・医療:M&Aディール及び事業提携情報
    Summary PT. SOHO Industri Pharmasi (PT SOHO), a subsidiary of SOHO Global Health, is a pharmaceutical company that offers ethical, consumer health, herbal medicine and natural products. The company’s products include analgesic, anti-inflammatory, antipyretic, antibiotics, antifungal, antihistamine a …
  • East Japan Railway Co:戦略・SWOT・企業財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Synedgen Inc:医療機器:M&Aディール及び事業提携情報
    Summary Synedgen Inc (Synedgen) is a biotechnology company that discovers and develops polysaccharide-based drugs, which enhance and mimic the innate immune system. The company’s pipeline products include SYGN305, SYGN399, SYGN303, SYGN313 and SYGN309. Synedgen develops products for the treatment of …
  • Rexel S.A.:企業の戦略・SWOT・財務情報
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Centrica Plc (CNA)-エネルギー分野:企業M&A・提携分析
    Summary Centrica plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Compumedics Ltd (CMP):企業の財務・戦略的SWOT分析
    Summary Compumedics Ltd (Compumedics) is a medical device company. It develops and commercializes computer-based medical products. The company designs, develops and commercializes computer aided medical diagnostic systems. It provides product categories such as sleep diagnostics, neurology diagnosti …
  • Astex Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Astex Pharmaceuticals Inc (Astex Pharmaceuticals), is a novel drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. It discovers and develops small molecule treatments. The company’s lead product, Dacogen (indicated for the treatment of myel …
  • Unfors RaySafe AB:医療機器:M&Aディール及び事業提携情報
    Summary Unfors RaySafe AB (Unfors), formerly Unfors Instruments AB, is a subsidiary of Fluke Biomedical, medical device company that provides solution for the X-ray room consisting of products which collect radiation. The company’s products include RaySafe ThinX, RaySafe X2, RaySafe Solo, RaySafe Xi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆